Early RIBECCA results: ribociclib with letrozole for metastatic breast cancer

Early RIBECCA results: ribociclib with letrozole for metastatic breast cancer

User Photo
VJOncology

1 year
196 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
In this interview, Peter Fasching, MD, from University Hospital Erlangen, Erlangen, Germany, discusses the design and the initial safety results of the Phase III RIBECCA trial (NCT03096847) investigating the efficacy and safety of ribociclib with letrozole for HR+ metastatic or advanced breast cancer. Dr Fasching then compares their results with the previous MONALEESA-2 (NCT01958021) and MONALEESA-3 (NCT02422615) studies, which also focused on the use of ribociclib for breast cancer. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.
Up Next Autoplay